Сасо-2 INTESTINAL PERMEABILITY AND Pgp-AFFINITY OF PHOSPHAZIDE
Abstract
In this work the intestinal permeability of phospazide in vitro was investigated using Caco-2 cell model in apical-basolateral (A-B) and basolateral-apical (B-A) directions as well as with the option of adding of P-glycoprotein (Pgp) inhibitor cyclosporine A. The following standard substances were used: ranitidine and propranolol. Papp values of test and standard substances were obtained. The obtained data were compared with the values (A) log P for the test and standard substances. According the results of this study, the phosphatide presumably has a low intestinal permeability in terms of BCS. The affinity of phosphazide for the efflux transporter Pgp was demonstrated.
About the Authors
D. Yu. Grebenkin
Institute of Biochemical Technology and Nanotechnology Peoples' Friendship University of Russia;
ExacteLabs Company
Russian Federation
Russian Federation
Ya. M. Stanishevskiy
Institute of Biochemical Technology and Nanotechnology Peoples' Friendship University of Russia
Russian Federation
Russian Federation
I. E. Shohin
Center of Pharmaceutical Analytics Ltd
Russian Federation
Russian Federation
A. M. Stoinova
Institute of Biochemical Technology and Nanotechnology Peoples' Friendship University of Russia
Russian Federation
Russian Federation
M. A. Karpova
LLC «Research Institute ChemRar»
Russian Federation
Russian Federation
A. G. Koryakova
LLC «Research Institute ChemRar»
Russian Federation
Russian Federation
A. V. Ryabova
ExacteLabs Company
Russian Federation
Russian Federation
B. V. Brovchenko
LLC «AZT PHARMA K.B.»
Russian Federation
Russian Federation
A. A. Smirnov
LLC «AZT PHARMA K.B.»
Russian Federation
Russian Federation
References
1. P. Artursson, K. Palm, K Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport // Advanced drug delivery reviews. 2001. Т. 46. № 1. С. 27-43.
2. Draft guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system / FDA. 2015.
3. Н.В. Сизова и др. Фосфазид - отечественный препарат для лечения ВИЧ-инфекции. Второе рождение //ВИЧ-инфекция и иммуносупрессии. 2012. Т. 4. № 2. С. 45-54.
4. А.Ф. Хохлов, Б.В. Бровченко, А.А. Смирнов. Разработка и регистрация комбинированного лекарственного препарата для лечения ВИЧ-инфекции на основе нуклеозидных ингибиторов обратной транскриптазы (НИОТ)-фосфазида и ламивудина // Разработка и регистрация лекарственных средств. 2016. № 1. С. 48-60.
5. И.Е. Шохин и др. Изучение кинетики растворения инновационного антиретровирусного препарата Никавир® и его фиксированной комбинации с ламивудином (Фосфаладин®) // Разработка и регистрация лекарственных средств. 2016. №. 2. С. 136-145.
6. J. Phillips, А. Arena. Optimization of Caco-2 cell growth and differentiation for drug transport studies / Millipore Corporation Protocol Note PC1060EN00. 2003.
7. Интерактивные расчеты. URL: http://www.vcclab.org/web/alogps (дата обращения 08.2017).
Review
For citations:
Grebenkin D.Yu., Stanishevskiy Ya.M., Shohin I.E., Stoinova A.M., Karpova M.A., Koryakova A.G., Ryabova A.V., Brovchenko B.V., Smirnov A.A. Сасо-2 INTESTINAL PERMEABILITY AND Pgp-AFFINITY OF PHOSPHAZIDE. Drug development & registration. 2017;(4):238-242. (In Russ.)
Views:
892
Email this article 